ClinicalTrials.gg
CompletedNCT00244608Updated Jan 24, 2011

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

A Phase 3 interventional study of Budesonide/Formoterol Turbuhaler and Budesonide Turbuhaler (Pulmicort) in Asthma, sponsored by AstraZeneca. Completed at 22 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
58th of 108
100 · median 124
Started
2005
with 5 others
Phase 3
51 of 110
3 open now
Registered
10th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 58th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2005, is one of 51 in phase 3, and was the 10th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma for at least 6 months
  • Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one

Exclusion criteria

Exclusion Criteria:

  • Respiratory infection affecting asthma within 30 days prior to study
  • Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study
  • Any significant disease or disorder that may jeopardize the safety of the patient
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in eosinophils in bronchial biopsies (first and last visit) and in sputum (5 times during the 12-month treatment period)

Secondary outcomes

  1. Immunopathology and remodeling in biopsies

  2. Immunopathology and mediators in induced sputum

  3. Severe asthma exacerbations (number of and time to first)

  4. Forced expiratory volume in 1 second (FEV1)

  5. As-needed use

  6. Safety variables, including adverse events and vital signs

  7. All variables assessed over the 12-month treatment period

07

Study locations

22 sites
  • Research Site
    Copenhagen, Denmark
  • Research Site
    Ålborg, Denmark
  • Research Site
    Århus C, Denmark
  • Research Site
    Montpellier, France
  • Research Site
    Pessac, France
  • Research Site
    Hannover, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Marburg, Germany
  • Research Site
    Baraclado, Spain
  • Research Site
    Barcelona No. 40, Spain
  • Research Site
    Barcelona, No. 42, Spain
  • Research Site
    Göteborg, Sweden
  • Research Site
    Lund, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Umeå, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Glasgow, United Kingdom
  • Research Site
    Leicester, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Newcastle-Upon-Tyne, United Kingdom
  • Research Site
    Southampton, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2005
First posted
Oct 27, 2005
Start
May 2005
CompletionActual
Mar 2007
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00244608
Lead sponsor
AstraZeneca
First posted
Oct 27, 2005
Start date
May 2005
Completion
Mar 2007
Last update
Jan 24, 2011

Study contacts

AstraZeneca Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion